The FDA’s CMC Development and Readiness Pilot (CDRP) Program: What Sponsors Need to Know

In August 2023, the U.S. Food and Drug Administration (FDA) announced the launch of the Chemistry, Manufacturing, and Controls Development and Readiness Pilot (CDRP) Program. This initiative is designed to help sponsors of certain accelerated development products better align their CMC strategies with the FDA early in the development process. It is intended to help ensure that the CMC readiness for marketing (i.e. the quality, consistency, manufacturing, etc.) keeps pace with the faster clinical timelines, so that product approvals are not held up by CMC bottlenecks. The program was created in recognition of the fact that CMC issues are a leading cause of delays in regulatory review and product launches, especially for products on accelerated pathways.

Key Features / What the Program Offers

• Increased interaction between FDA and the sponsor during development. Sponsors admitted into the program get to have two additional Type B CMC meetings with the FDA beyond the usual meetings, plus additional time‑bound, substantive CMC‑focused discussions.  

• The FDA assembles a full interdisciplinary review team (for CMC readiness) to help guide the sponsor.  

• Use of science‑ and risk‑based regulatory approaches, where appropriate, to streamline or tailor what is required, helping avoid delays.  

• The pilot limits the number of participants per fiscal year so it can manage resources and allow for balanced learning. Typically, no more than nine proposals per fiscal year, with roughly two thirds being biologics/CBER‑regulated, and one third CDER (drugs)‑regulated.  

‍

Who Is Eligible?

• Products must already have an Investigational New Drug (IND) application in place.

• Are being developed under an expedited program designation (e.g., Breakthrough Therapy, Regenerative Medicine Advanced Therapy (RMAT), Fast Track).

• Novelty of the product, high expected clinical benefit of earlier access for patients

• Complex manufacturing process, with anticipated CMC challenges

Selection is competitive, and the FDA has emphasized that this is not a broad program—it is focused on cases where early alignment on CMC is most critical.

‍

What It Means: Advantages & Challenges

Advantages:

• Faster alignment of CMC readiness with clinical development so that when the efficacy/safety data are ready, the manufacturing/quality side is also ready (or nearly so), reducing delays in submissions or approvals.

• Earlier feedback from FDA about what is needed, and when; potential to avoid surprises or requests for major changes late in development.

• Possibly more efficient regulatory path, leveraging risk/sci‑based approaches to reduce unnecessary burden where safe to do so.

Challenges / Things to Watch:

• Sponsors must have good planning and resources to meet aggressive timelines; the CMC tasks are often time‑ and resource‑intensive (e.g. process validation, stability studies, scaling up manufacturing).

• Even with expedited CMC readiness, there may still be regulatory, manufacturing, or quality issues that arise late. Being in the pilot doesn’t guarantee a faster approval, but it improves chances.

• Limited slots: because only a few proposals are accepted each year, many eligible projects may not get accepted.

For the FDA, the program represents a way to support innovation while maintaining rigorous quality standards.

‍

Enhance Your CDRP Success with Specialized CMC Support, Providing:

Regulatory Intelligence and Strategy

• Consultants bring deep knowledge of FDA expectations.

• Help craft a realistic and risk-informed CMC roadmap aligned with the CDRP timeline.

Clear, Compliant, and Audit-Ready Documentation

• Technical writers ensure:

• CMC Development Plans are clear and defensible.

• Modules (e.g., 3.2.S, 3.2.P) are consistent, aligned, and submission-ready.

• Prevents rejection or major information requests.

Meeting Preparation and Follow-Up

• Help prepare for extra Type B CMC meetings and informal FDA engagements offered under CDRP.

• Support development of briefing packages, response strategies, and meeting minutes.

Scalability and Speed

• External CMC experts can:

• Ramp up quickly for intense pre-submission periods.

• Fill gaps in internal knowledge, especially for novel platforms or modalities.

Risk Mitigation Benefits

• Poorly written or disorganized CMC documentation can:

• Delay FDA feedback.

• Result in clinical hold or approval delays.

• CMC consultants reduce the risk of “surprise deficiencies” late in the process.

‍

Conclusion

The FDA’s CMC Development and Readiness Pilot (CDRP) Program reflects a growing recognition that CMC is often the rate-limiting step in drug approvals—especially for expedited pathways. By engaging early and strategically, sponsors can reduce regulatory risk and accelerate the path to patients.

Whether or not your program is selected for CDRP, the underlying message is the same: investing in CMC readiness early pays dividends later.

Contact GLOBAL today to learn how our experienced CMC team can support your regulatory strategy and help you avoid costly delays.

‍